Argatroban SK-3 inhibitor 1 8 nM and blocked ligand-stimulated

8 nM and blocked ligand-stimulated activation of a chimeric EGFR-Mer protein

Peng Cho Tang

ZM-306416 selective anti-proliferative effect toward the EGFR addicted NSCLC cell lines H3255 and HCC4011 (IC50=0

Smiles: CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)C1=CC=C(N)C(Cl)=C1)C(C)(C)C

4-tetrahydronaphthalen-1-yl)carbamoyl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate InChI Key CDDABGWUXFFTGQ-MLSLTINKSA-N Smiles CN([C@H](C(N[C@H](C(N1C[C@@H](NC(COCCOCCOCCOCCN)=O)C[C@H]1C(N[C@@H]2CCCC3=CC=CC=C23)=O)=O)C4CCCCC4)=O)C)C(OC(C)(C)C)=O References

Argatroban SK-3 inhibitor 1 8 nM and blocked ligand-stimulatedArgatroban is an anticoagulant that is a direct thrombin inhibitor. Argatroban was approved in 2000 for prophylaxis or treatment of thrombosis in patients with heparin induced thrombocytopenia (HIT). Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban exerts its anticoagulant effects by inhibiting thrombin catalyzed or induced reactions, including fibrin formation; activation of coagulation factors